» Articles » PMID: 16645594

Distinct Roles for IL-1 Receptor Type I Signaling in Early Versus Established Leishmania Major Infections

Overview
Publisher Elsevier
Specialty Dermatology
Date 2006 Apr 29
PMID 16645594
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

IL-1alpha/beta released by infected dendritic cells (DC) plays a critical role in the development of protective immunity against Leishmania major. Previous studies demonstrated that treatment of susceptible BALB/c mice with IL-1alpha during T-cell priming (days 1-3 post-infection) induced T helper (Th)1-mediated protection. In contrast, we now demonstrate that prolonged treatment with IL-1alpha (for 3 weeks) worsened disease outcome. To characterize the receptor involved, L. major infections in IL-1 receptor type I (IL-1RI) knockout mice were studied. In C57BL/6 IL-1RI-/- mice, the IL-1alpha-mediated protective effect was abrogated. The course of high-dose infection (2 x 10(5) parasites) in IL-1RI-/- mice was not different from controls. Surprisingly, in low-dose infections (10(3) parasites), IL-1RI-/- mice developed approximately 50% smaller lesions compared to wild types, decreased parasite loads and increased IFNgamma/IL-4 ratios. Interestingly, naive Th0 and Th2, but not Th1, cells expressed IL-1RI ex vivo. We conclude that IL-1RI mediates the effect of IL-1alpha in leishmaniasis in C57BL/6 mice. In addition, IL-1 appears to play distinct roles in Th education and maintenance. In early phases of physiologically relevant, low-dose L. major infections, IL-1 facilitates Th1 development from Th0 cells, whereas later on IL-1RI signaling promotes Th2 expansion and worsens disease outcome. Effects of IL-1 on disease outcome may be related to levels of IL-1RI on Th subpopulations.

Citing Articles

Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.

Lafleur A, Daffis S, Mowbray C, Arana B Vaccines (Basel). 2024; 12(10).

PMID: 39460345 PMC: 11511131. DOI: 10.3390/vaccines12101179.


Multiomic profiling of cutaneous leishmaniasis infections reveals microbiota-driven mechanisms underlying disease severity.

Farias Amorim C, Lovins V, Singh T, Novais F, Harris J, Lago A Sci Transl Med. 2023; 15(718):eadh1469.

PMID: 37851822 PMC: 10627035. DOI: 10.1126/scitranslmed.adh1469.


The cytokine/chemokine response in /HIV infection and co-infection.

Maksoud S, Hokayem J Heliyon. 2023; 9(4):e15055.

PMID: 37082641 PMC: 10112040. DOI: 10.1016/j.heliyon.2023.e15055.


Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to infection.

Osero B, Aruleba R, Brombacher F, Hurdayal R Cytokine X. 2021; 2(4):100043.

PMID: 33415318 PMC: 7773805. DOI: 10.1016/j.cytox.2020.100043.


Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis.

Farias Amorim C, Novais F, Nguyen B, Misic A, Carvalho L, Carvalho E Sci Transl Med. 2019; 11(519).

PMID: 31748229 PMC: 7068779. DOI: 10.1126/scitranslmed.aax4204.